CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-07-31 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −2,270 | $27.56 | $63K | 1,061,255 |
| 2024-07-31 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +991 | $2.48 | $2K | 991 |
| 2024-07-31 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −991 | $27.53 | $27K | 0 |
| 2024-07-31 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −991 | 203,379 | ||
| 2024-07-31 | Heyman Richard A. Director | Sale 10b5-1 | −1,702 | $27.51 | $47K | 131,643 |
| 2024-07-31 | Heyman Richard A. Director | Sale 10b5-1 | −649 | $27.50 | $18K | 27,918 |
| 2024-07-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −11,797 | $26.69 | $315K | 1,093,238 |
| 2024-07-29 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −203 | $27.43 | $6K | 1,093,035 |
| 2024-07-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +5,250 | $2.48 | $13K | 5,250 |
| 2024-07-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −5,189 | $26.67 | $138K | 61 |
| 2024-07-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −61 | $27.44 | $2K | 0 |
| 2024-07-29 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −5,250 | 204,370 | ||
| 2024-07-25 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −3,793 | $24.53 | $93K | 1,071,732 |
| 2024-07-25 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −8,164 | $25.10 | $205K | 1,063,568 |
| 2024-07-25 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −43 | $25.83 | $1K | 1,063,525 |
| 2024-07-16 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −1,547 | $25.01 | $39K | 344,027 |
| 2024-07-15 | Heyman Richard A. Director | Sale 10b5-1 | −1,270 | $24.80 | $31K | 133,345 |
| 2024-07-15 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −30,978 | $25.05 | $776K | 345,574 |
| 2024-07-12 | Patel Anish CHIEF OPERATING OFFICER | Sale 10b5-1 | −17,475 | $25.07 | $438K | 376,552 |
| 2024-07-12 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +3,000 | $2.48 | $7K | 3,000 |
Page 18 of 37 · 724 trades